Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2006-01-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Levetiracetam in Central Pain in Multiple Sclerosis(MS)
NCT00423527
Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury
NCT00252954
Levetiracetam for Treatment of Pain Associated With Fibromyalgia
NCT00254657
Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
NCT02002819
The Effect of Levetiracetam on the Postmastectomy Pain Syndrome
NCT00262262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levetiracetam
Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* painful symptoms of polyneuropathy for at least 6 months
* confirmed diagnosis of polyneuropathy
* baseline pain score of 4 or more (0 to 10 point scale)
* pain at least 4 days a week
* adequate anticonceptive treatment for women with childbearing potential
* informed consent
Exclusion Criteria
* previous allergic reactions towards levetiracetam
* known adverse drug reactions on levetiracetam
* pregnancy
* severe disease
* inability to follow study protocol
* treatment with antidepressants, other anticonvulsants or opioids
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Odense University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Søren H Sindrup, Professor
Role: STUDY_CHAIR
Department of Neurology, Odense Unviersity Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurology, Odense University Hospital
Odense C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
keppra2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.